Agilent Technologies, Inc.
NYSE:AMedical - Diagnostics & Research
+$3.04 today
- Market cap
- $50.00B
- Beta
- 1.26
- P/E (TTM)
- 25.5
- EPS (TTM)
- $5.00
- Dividend yield
- 0.59%
Volume 2.48M
Average 2.24M
A Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Agilent Technologies, Inc.NYSE: A
Financing Cash Flow · Q3 FY2026 · quarter ended Jul 2026
Financing cash flow turns positive
Q3 FY2026 financing cash flow was $471M, compared with -$219M a year earlier. Trailing-twelve-month financing cash flow was -$95M. Over 3 fiscal years it compounded at -19.5% a year.
Context
- Financing cash flow amounted to 10.3% of revenue in FY2025, down 1.3 pp from a year earlier.
- Financing cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $471M or moves back toward the trailing-twelve-month quarterly average of -$23.75M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (715M) USD
- Year-over-year change
- +4.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | (715M) | +4.9% |
| FY2024 | 2024-10-31 | (752M) | +19.1% |
| FY2023 | 2023-10-31 | (930M) | +32.2% |
| FY2022 | 2022-10-31 | (1.37B) | -97.1% |
| FY2021 | 2021-10-31 | (696M) | — |
Financing Cash Flow vs competitors
How A compares with its peers on the latest reported figures
- A's LTM Jul 2026 financing cash flow of $95M is the 8th largest of the 9 companies compared; the peer median is $248.75M.
- Its year-over-year change of -80.6% is the lowest of 9, against a peer median of +9.4%.
- Financing cash flow amounts to 1.3% of revenue for A, versus a peer median of 13.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $8.32B | +240.6% | +4.8% | 32.5% | |
| LTM Sep 2026 | $985M | +118.3% | — | 2.1% | |
| LTM Jun 2026 | $817.11M | +0.5% | +1.8% | 19.8% | |
| LTM Jul 2026 | $503.44M | -67.2% | +8.9% | 17.3% | |
| LTM Jul 2026 | $399.93M | -26.6% | -22.5% | 8.6% | |
| LTM Jun 2026 | $376.41M | +18.3% | +12.5% | 17.9% | |
| LTM Jun 2026 | $121.1M | -66.0% | — | 4.7% | |
| LTM Jul 2026 | $95M | -80.6% | -19.5% | 1.3% | |
| LTM Jun 2026 | $35.1M | +205.1% | — | 1.0% | |
| Peer median (excluding A) | $248.75M | +9.4% | +4.8% | 13.0% | |
Competitors are the stored peer set for A. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | 1.21B | 1.25B | 1.24B | 1.29B | 434M |
| Depreciation & Amortization | 321M | 317M | 271M | 257M | 288M |
| Deferred Income Tax | 14M | 8M | (56M) | (64M) | (130M) |
| Stock-Based Compensation | 110M | 125M | 111M | 129M | 128M |
| Change in Working Capital | (102M) | (478M) | (116M) | 83M | (58M) |
| Accounts Receivables | (128M) | (321M) | 132M | 7M | (149M) |
| Inventory | (136M) | (248M) | (33M) | 34M | 45M |
| Accounts Payables | 64M | 121M | (171M) | 103M | 16M |
| Other Working Capital | 98M | (30M) | (44M) | (61M) | 30M |
| Other Non-Cash Items | (68M) | 86M | 322M | 57M | 897M |
| Operating Cash Flow | 1.49B | 1.31B | 1.77B | 1.75B | 1.56B |
| Capital Expenditures | (189M) | (291M) | (298M) | (378M) | (407M) |
| Acquisitions (Net) | (546M) | (52M) | (1M) | (862M) | 4M |
| Purchases of Investments | (22M) | (13M) | (8M) | (5M) | 0 |
| Sales of Investments | 12M | 22M | 5M | 0 | 8M |
| Other Investing Activities | (4M) | (4M) | (8M) | (13M) | (199M) |
| Investing Cash Flow | (749M) | (338M) | (310M) | (1.26B) | (394M) |
| Debt Repayment | 356M | 26M | (35M) | 637M | (41M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 72M |
| Common Stock Repurchased | (788M) | (1.14B) | (575M) | (1.15B) | (425M) |
| Dividends Paid | (236M) | (250M) | (265M) | (274M) | (282M) |
| Other Financing Activities | (28M) | 58M | (55M) | 35M | (39M) |
| Financing Cash Flow | (696M) | (1.37B) | (930M) | (752M) | (715M) |
| Effect of Forex Changes | 3M | (36M) | 5M | (2M) | 9M |
| Net Change in Cash | 43M | (434M) | 537M | (261M) | 459M |
| Free Cash Flow | 1.3B | 1.02B | 1.47B | 1.37B | 1.15B |
Agilent Technologies, Inc.
NYSE:A
Intrinsic Alpha fair value
Locked
Current Price
$177.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.